GSK

News

JPM: GSK announces $1.4bn deal to buy asthma biotech Aiolos

GSK has taken another step towards rebuilding its respiratory pipeline with a $1.4 billion agreement to buy Aiolos Bio and its lead drug AIO-001 for asthma and other indic

News

FDA holds back MSD’s chronic cough drug again

MSD will have to return to the drawing board to chart a course for US approval of its chronic cough treatment gefapixant.

News

GSK taps Hansoh for another cancer ADC candidate

GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront

News

New RUBY readout buoys GSK’s Jemperli in endometrial cancer

GSK has said that a regimen of PD-1 inhibitor Jemperli with PARP inhibitor Zejula has shown efficacy in the second stage of the RUBY trial, which could open up wider use i

News

Is GSK’s Blenrep heading for a renaissance?

A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the

News

Sosei sees $3bn sales potential for GSK's IBD discard

Sosei Heptares has lost GSK as a partner for an inflammatory bowel disease (IBD) drug candidate GSK4381406, but says it will take the programme forward as it has significa

JPM: GSK announces $1.4bn deal to buy asthma biotech Aiolos

FDA holds back MSD’s chronic cough drug again

GSK taps Hansoh for another cancer ADC candidate

New RUBY readout buoys GSK’s Jemperli in endometrial cancer

Is GSK’s Blenrep heading for a renaissance?

Sosei sees $3bn sales potential for GSK's IBD discard

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

GSK

Editor's Picks